Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics has been granted a new patent in China for the salt form of its leading drug candidate, mesdopetam, which is under development for treating levodopa-induced dyskinesias in Parkinson’s disease patients. This patent extension enhances the market exclusivity of mesdopetam, potentially extending its protection into the mid-2040s, thereby increasing its value and strengthening IRLAB’s position in major markets, including the USA, Europe, and Japan.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing innovative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing a portfolio of drug candidates, including mesdopetam for levodopa-induced dyskinesias, pirepemat for reducing fall frequency, and IRL757 for treating apathy in neurodegenerative disorders. IRLAB utilizes its proprietary Integrative Screening Process (ISP) for drug discovery and is listed on Nasdaq Stockholm.
Average Trading Volume: 131,326
Technical Sentiment Signal: Sell
Current Market Cap: SEK255M
Learn more about IRLAB.A stock on TipRanks’ Stock Analysis page.